Core Viewpoint - CATL (Contemporary Amperex Technology Co., Limited) has demonstrated significant financial growth in Q3 2025, achieving record profits and revenue, while also expanding its market presence internationally and diversifying its business model towards energy storage and consumer markets [4][6][14]. Financial Performance - In Q3 2025, CATL reported revenue of 1041.86 billion yuan, a year-on-year increase of 12.90%, and a net profit of 185.49 billion yuan, up 41.21%, marking the highest quarterly profit in the company's history [4][11]. - For the first three quarters of 2025, total revenue reached 2830.72 billion yuan, with a year-on-year growth of 9.28%, and net profit increased by 36.20% to 490.34 billion yuan [5][6]. - The company's operating cash flow for the first three quarters was 806.6 billion yuan, reflecting a 19.6% increase, indicating strong self-financing capabilities [7][11]. Profitability and Margins - CATL's net profit margin in Q3 reached 19.1%, an increase of 4.1 percentage points compared to the same period last year, highlighting improved profitability [15]. - The company achieved an average daily profit of over 200 million yuan in Q3, compared to less than 140 million yuan in the previous year [13]. Market Position and Challenges - Despite maintaining a leading position in the global electric vehicle battery market with a 36.8% share, CATL's market share has slightly declined from 37.7% year-on-year [24]. - In the domestic market, CATL's share decreased by 3.1 percentage points to 42.75%, marking the lowest level in five years [24]. International Expansion and Strategy - CATL's overseas revenue reached 612 billion yuan in the first half of 2025, accounting for 34.22% of total revenue, with plans to increase overseas production capacity to 40% by 2026 [27]. - The company is focusing on expanding its presence in Europe and North America, with significant market shares of 35% and 28% respectively [28]. - The funds raised from the Hong Kong IPO are primarily allocated for overseas capacity construction, particularly in Hungary [27][29]. Diversification into Energy Storage - CATL is increasing its focus on energy storage systems, which accounted for approximately 20% of its total shipments in Q3 2025 [31]. - The company is expanding its production capacity for energy storage batteries across multiple locations in China, anticipating significant demand from data centers [31]. New Business Ventures - CATL is entering the consumer market with its battery swapping service, targeting the C-end market for the first time, which could open new growth avenues [33][34].

Core Viewpoint - The company, Zai Lab (09688.HK), announced that its board's audit committee will review and approve the unaudited quarterly performance for the third quarter ending September 30, 2025, on November 6, 2025, in accordance with US GAAP and SEC regulations [1] Group 1 - The board's audit committee is scheduled to meet on November 6, 2025 [1] - The meeting will focus on the unaudited quarterly results for the three and nine months ending September 30, 2025 [1] - The results will be prepared in compliance with US GAAP and applicable SEC rules [1]

Zai Lab Limited 再鼎醫藥有限公司 * （於開曼群島註冊成立的有限公司） （股份代號：9688） 審核委員會行動通告及 2025 年第三季度業績公告的發佈日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不會對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任何損失承擔任何責任。 在第三季度業績獲批准及發佈後，本公司管理層計劃在 2025 年 11 月 6 日（星期四，美國東部時間） 上午 8:00/2025 年 11 月 6 日（星期四，香港時間）下午 9:00 舉行現場業績電話會議及網絡直播，以討 論第三季度業績並回答提問。有意參會人士可透過本公司網站 http://ir.zailaboratory.com 參與網絡直播。 所有參與者均須於電話會議前透過下文提供的連結完成線上登記流程。登記後，參與者將收到提供撥 號詳情的確認郵件。 網絡直播登記連結： https://edge.media-server.com/mmc/p/svanah67 拨入登記連結：https://register-conf.med ...

- 1 - (A) 人數。委員會應由至少三名成員組成。 (B) 獨立性。委員會的每名成員均應符合納斯達克全球市場（「納斯達克」）及香 港聯合交易所有限公司證券上市規則（「香港上市規則」）的適用獨立性 要求，並符合「獨立董事」的資格。 (C) 主席。除非主席由董事會委任，否則委員會成員應通過委員會全體成員的 多數票指定一名主席。主席應領導委員會，包括制定會議議程、主持會議、 分配小組委員會任務及代表委員會向董事會報告。 (D) 關於成員資格的決定。委員會的成員應由董事會委任並可由董事會酌情罷 免。董事會將至少每年評估是否符合上述成員資格要求。 再鼎醫藥有限公司董事會 提名及企業管治委員會章程 （於2025年10月22日獲董事會採納） I. 宗旨和權限。 再鼎醫藥有限公司（「公司」）董事會（「董事會」）下設的提名及企業管治委員會（「委 員會」）的宗旨是履行董事會授予有關企業管治及董事提名的職責。 II. 組成。 III. 程序和管理。 (A) 董事會和委員會事務；企業管治。 (1) 董事提名人選。委員會應按董事會批准的標準物色有資格成為董事會成 員的人士，接收並審查有關合格人士的提名及審查首席執行官提出的推 薦； ...

Core Viewpoint - The Hong Kong stock market's innovative drug sector is experiencing a decline, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping over 3.5% as of the report, indicating a potential buying opportunity for investors despite the downturn [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a trading volume exceeding 200 million yuan, continuing to exhibit high premiums in the market [1] - The innovative drug sector faced a significant drop recently, with the ETF attracting over 75 million yuan in a single day, totaling over 120 million yuan in the last four days [1] Group 2: Recent Developments - The ESMO 2025 conference recently showcased positive data for several core projects of Chinese innovative drugs [1] - On October 22, Innovent Biologics announced a global strategic partnership with Takeda Pharmaceutical worth 11.4 billion USD, setting a record for the value of business development (BD) transactions in China's innovative drug sector, involving three product rights and pipeline development [1] Group 3: Future Outlook - Huafu Securities suggests that the recent adjustments in the Hong Kong innovative drug sector may present a significant opportunity for investment in late October [1] - The long-term outlook remains positive for companies with commercialization capabilities and rich pipelines, particularly in BioPharma, potential BD targets, and cutting-edge technology [1] - The innovative drug industry is expected to benefit from interest rate cuts, with performance anticipated to improve, and the end-of-year BD period may act as a catalyst for growth [1] Group 4: Index Composition - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its linked fund (025220) passively track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which includes top ten weighted stocks such as BeiGene, China Biologic Products, Innovent Biologics, and others [1]

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 0.46% on October 20, with a trading volume of 907 million yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of October 17, 2024, the fund's shares totaled 8.134 billion, with a total size of 6.968 billion yuan, reflecting a significant increase in both shares and size compared to the previous year [1] Fund Performance - The fund has seen a remarkable increase of 1957.27% in shares and 1744.35% in size since December 31, 2023 [1] - The fund's cumulative trading amount over the last 20 trading days reached 27.487 billion yuan, with an average daily trading amount of 1.374 billion yuan [1] - Year-to-date, the cumulative trading amount is 224.063 billion yuan, averaging 1.173 billion yuan per day over 191 trading days [1] Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 71.34% during the management period [2] - The fund's top holdings include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant percentages of the portfolio allocated to these stocks [2]

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 2.42% on October 16, with a trading volume of 1.486 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of October 15, 2024, the fund's shares reached 8.213 billion, with a total size of 7.102 billion yuan, reflecting a significant increase of 1977.25% in shares and 1779.88% in size compared to December 31, 2023 [1] Fund Performance - The current fund manager, Ma Jun, has achieved a return of 68.94% since taking over the fund on January 3, 2024 [2] - The ETF's top holdings include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant percentages of the portfolio allocated to these stocks [2] Trading Activity - Over the last 20 trading days, the ETF recorded a cumulative trading amount of 30.962 billion yuan, averaging 1.548 billion yuan per day [1] - Since the beginning of the year, the ETF has seen a total trading amount of 222.219 billion yuan over 189 trading days, averaging 1.176 billion yuan per day [1]

Market Performance - The Hong Kong stock market continued its decline, with notable drops in several biotech companies [1] - Innovent Biologics (09969) fell by 11.19%, closing at 14.760, with a market capitalization of 26.021 billion and a year-to-date increase of 141.18% [2] - Rongchang Biologics (09995) decreased by 10.22%, with a latest price of 95.350 and a total market value of 53.74 billion, reflecting a year-to-date increase of 562.15% [2] - WuXi AppTec (02268) and WuXi Biologics (02269) experienced declines of 5.68% and 5.32%, respectively, with market caps of 89.818 billion and 1585.28 billion [2] - Other companies such as Fuhong Hanlin (02696) and Kelun-Biotech (06990) also saw declines of over 4% [1][2] Company Highlights - Innovent Biologics has shown a significant year-to-date performance increase of 141.18% despite the recent drop [2] - Rongchang Biologics has the highest year-to-date increase among the listed companies at 562.15% [2] - WuXi Biologics and WuXi AppTec have maintained strong year-to-date increases of 120.84% and 138.50%, respectively [2] - Fuhong Hanlin and Kelun-Biotech also reported substantial year-to-date increases of 205.49% and 199.33% [2]

Core Viewpoint - The Hong Kong biopharmaceutical stocks continued to decline, with significant drops in several key companies, indicating a bearish trend in the sector [1]. Group 1: Stock Performance - Innovent Biologics (09969) experienced a decline of 11.19%, with a latest price of 14.760 and a total market capitalization of 26.021 billion, despite a year-to-date increase of 141.18% [2]. - Rongchang Biologics (09995) fell by 10.22%, with a latest price of 95.350 and a market cap of 53.747 billion, showing a remarkable year-to-date increase of 562.15% [2]. - WuXi AppTec (02268) saw a decrease of 5.68%, with a latest price of 73.100 and a market cap of 89.818 billion, maintaining a year-to-date increase of 138.50% [2]. - WuXi Biologics (02269) dropped by 5.32%, with a latest price of 38.780 and a market cap of 158.528 billion, reflecting a year-to-date increase of 120.84% [2]. - Fuhong Hanlin (02696) declined by 4.42%, with a latest price of 72.400 and a market cap of 39.349 billion, showing a year-to-date increase of 205.49% [2]. - Kelun-Biotech (06990) decreased by 4.25%, with a latest price of 488.800 and a market cap of 113.981 billion, with a year-to-date increase of 199.33% [2]. - WuXi AppTec (02359) fell by 4.19%, with a latest price of 114.400 and a market cap of 339.275 billion, reflecting a year-to-date increase of 109.21% [2]. - Gendicine (09688) saw a decrease of 2.83%, with a latest price of 25.440 and a market cap of 28.432 billion, with a year-to-date increase of 21.72% [2]. - CanSino Biologics (09926) declined by 2.05%, with a latest price of 128.800 and a market cap of 118.643 billion, reflecting a year-to-date increase of 112.19% [2]. - Junshi Biosciences (01877) fell by 2.02%, with a latest price of 29.100 and a market cap of 29.877 billion, showing a year-to-date increase of 151.30% [2].

Core Viewpoint - The domestic innovative drug industry is transitioning from a follower to FIC/BIC innovation, supported by engineer dividends, abundant clinical resources, and favorable policies, indicating a qualitative improvement as it enters the 2.0 era [1][2] Group 1: Industry Development - The innovative drug sector is expected to benefit from policy reforms in payment systems, enhancing the profitability of innovative drug companies as they commercialize domestic products [2] - The upcoming ESMO conference in mid-October is anticipated to provide new investment opportunities through the release of relevant clinical data and business development (BD) activities [2] Group 2: Investment Climate - The investment landscape has improved since early this year, with a notable reversal in the financing trend for the innovative drug industry, particularly in the A/H market [3] - The recovery of IPO projects and financing activities in the secondary market is expected to positively impact investment data in Q3, benefiting domestic CROs and upstream research sectors [3] Group 3: Policy Support - Continuous advancement of commercial medical insurance policies since 2025 is likely to accelerate payment system reforms, easing supply-demand conflicts and supporting domestic innovation [4] - Fiscal policy enhancements are expected to increase market interest in domestic medical equipment stocks [4] Group 4: Target Companies - A-share targets include: BeiGene (688235.SH), Hengrui Medicine (600276.SH), Kelun Pharmaceutical (002422.SZ), WuXi AppTec (603259.SH), Tigermed (300347.SZ), New Industry (300832.SZ), BGI Genomics (688114.SH), Huatai Medical (688617.SH), and Dian Diagnostics (300244.SZ) [5] - H-share targets include: Kelun Biotech (06990), CSPC Pharmaceutical (01093), China Biologic Products (01177), CanSino Biologics (09926), WuXi Biologics (02269), Junshi Biosciences (01877), and Zai Lab (09688) [5]